Kura Oncology (NASDAQ:KURA) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $9.81 and traded as low as $7.47. Kura Oncology shares last traded at $7.61, with a volume of 8,211,639 shares trading hands.

Wall Street Analyst Weigh In

KURA has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Wednesday, October 14th. UBS Group reissued a “buy” rating on shares of Kura Oncology in a report on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, October 15th. Wedbush increased their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research note on Monday, August 24th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $25.35.

Kura Oncology Price Performance

The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm’s 50 day simple moving average is $10.94 and its 200 day simple moving average is $9.81. The company has a market capitalization of $676.99 million, a PE ratio of -2.26 and a beta of 0.56.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. As a group, research analysts anticipate that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Insider Activity at Kura Oncology

In other news, CEO Troy Wilson acquired 100,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was acquired at an average price of $11.12 per share, with a total value of $1,112,000.00. Following the completion of the purchase, the chief executive officer directly owned 379,194 shares in the company, valued at approximately $4,216,637.28. This trade represents a 35.82% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian T. Powl sold 17,020 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.53, for a total value of $179,220.60. Following the transaction, the insider owned 152,249 shares of the company’s stock, valued at $1,603,181.97. This trade represents a 10.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 153,881 shares of company stock worth $1,708,183 in the last three months. 7.60% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. IFP Advisors Inc lifted its position in shares of Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kura Oncology by 14.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company’s stock worth $175,000 after purchasing an additional 2,104 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Kura Oncology by 11.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock worth $194,000 after purchasing an additional 2,304 shares during the last quarter. Sterling Capital Management LLC grew its holdings in shares of Kura Oncology by 842.5% in the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock worth $30,000 after purchasing an additional 2,519 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in Kura Oncology by 22.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock worth $154,000 after buying an additional 2,656 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.